Background: The lateral fusion mass for multilevel lumbar laminectomies with noninstrumented posterolateral fusions now often utilizes lamina autograft and bone marrow aspirate (BMA) mixed with one of two bone graft expanders: either Vitoss (Orthovita, Malvern, PA, USA) or NanOss Bioactive (Regeneration Technologies Corporation: RTI, Alachua, FL, USA). Methods: Here, we compared two sequential prospective the times to fusion, fusion rates, complications, and infection rates for two prospective cohorts of patients utilizing either Vitoss (first 213 patients) or NanOss (subsequent 45 patients) respectively, undergoing multilevel lumbar laminectomies (average 4.6 vs. 4.5 levels) with noninstrumented fusions (average 1.3 vs. 1.2 levels). Surgery addressed stenosis/ossification of the yellow ligament (OYL) (all patients), with subsets exhibiting degenerative spondylolisthesis synovial cysts, and disc disease. Fusion was documented by two independent neuroradiologists blinded to the study design, utilizing dynamic X-rays and two dimensional computed tomography (2D-CT) studies up to 6 months postoperatively, and up to 1 year where indicated. 
INTRODUCTION
Two successive prospective cohorts of patients underwent multilevel lumbar laminectomies with noninstrumented posterolateral lumbar fusions (PLF) utilizing lamina autograft and bone marrow aspirate (BMA) mixed with one of two bone graft expanders. The first 213 patients received Vitoss (Orthovita, Malvern, PA, USA), while the latter 45 patients received NanOss Bioactive (Regeneration Technologies Corporation (RTI: Alachua, FL, USA). We asked whether utilization of these two bone graft expanders would result in comparable times to fusion, rates of fusion versus pseudarthrosis, incidence of postoperative seromas, and infection.
METHODS

Vitoss
Vitoss, a form of Beta Tri-Calcium Phosphate (B-TCP), is a synthetic cancellous bone graft substitute/bone void filler that contains 39% calcium and 20% phosphorous, in a 1:5 ratio. [1] [2] [3] [4] 6] Vitoss' porous low-density construct is prepared by fusing nano particles (100 nm in diameter) that increase its microporosity (e.g., a scaffold that is 90% interconnected; pores ranging from 1 to 1000 microns) and fusion rates by facilitating bone ingrowth/infiltration, resorption, dissolution, and new bone formation.
NanOss Bioactive
NanOss' nano-crystalline conformation (15-100 nm) is similar to normal human bone crystals (25-500 nm) both in composition and shape; alternatively, other calcium phosphate crystals are typically 1000-10,000 nm in size. [7, 8] NanOss contains highly purified porcine collagen that is unwound producing much more surface area for the attachment of osteoclasts/osteoblasts. This manufactured extracellular matrix-bioscaffold facilitates greater cell infiltration/ostoconduction, and fusion, with an open scaffold that optimizes bone mineralization/ remodeling. 
Two prospective cohorts utilizing
Posterolateral fusion mass utilizing vitoss and NanOss
Posterolateral fusion masses applied over decorticated transverse processes utilized lamina autograft (first layer), supplemented with Vitoss or NanOss (second layer). Both products come in a 10 × 2.5 cm sheets that are readily soaked in 10 cc of BMA. Each sheet may be cut in half or quarters for better handling. For a one-level fusion, each side receives half a strip applied dorsal to the lamina autograft, while two-level fusions in larger patients, may occasionally warrant a full strip on each side.
Dynamic X-rays and two dimensional computed tomography (CT) documentation of fusion
All patients underwent dynamic X-rays (3, 4.5, and 6 months postoperatively) and two dimensional CT (2D-CT) studies (at 3 months and repeated as needed) until fusion or pseudarthrosis was documented (e.g. up to 1 year postoperatively). Studies were independently analyzed by two neuroradiologists blinded to the study design.
RESULTS
Patients in both groups also exhibited comparable; times to fusion; 5.3 months vs. 4.8 months [ Figures 1-4 and Table 2 ]. Despite the much greater number of patients in the Vitoss versus NanOss cohorts, both groups exhibited similar fusion rates; 210 (98.6%) of 213 Vitoss patients fused versus 100% fusion rate for the 45 NanOss patients. However, likely due to the larger number of patients in the Vitoss series, three patients exhibited pseudarthrosis (1.4%), two of whom had developed early wound infections (0.94%), while two others developed postoperative seromas (0.94%) warranting debridement. Alternatively, for the smaller sample of NanOss patients, no pseudarthroses, infections, or seromas were observed.
DISCUSSION
Prior studies documenting efficacy of Vitoss as a bone graft expander for fusion Efficacy of Vitoss as a bone graft expander for instrumented posterolateral lumbar fusions
Epstein previously documented the efficacy of Vitoss as a bone graft supplement/expander in two instrumented PLF studies. [1] In the 2006 study, Vitoss, BMA, and lamina autograft (50:50 mix) constituted the posterolateral fusion mass for 40 multilevel lumbar laminectomies (average 3.7 levels) with one (27 patients) or two level (13 patients) instrumented fusions. At 6 postoperative months, 26 of 27 single level procedures fused (1 pseudarthrosis), while 11 of 13 two level fusions (2 pseudarthroses) succeeded. In 2009, Vitoss, BMA, and lamina autograft were again successfully utilized to perform 100 posterolateral lumbar instrumented fusions. [3] For single-level fusions, 74 (93.7%) of 79 patients fused "early" (average 6.5 postoperative months), 2 (2.5%) fused "late" (average 6.5-12 months), while 3 (3.8%) exhibited pseudarthrosis. For two-segment fusions, 14 (66.7%) of 21 patients showed "early" fusions, 5 (23.8%) demonstrated "late" fusions, while 2 (9.5%) exhibited pseudarthroses.
Efficacy of Vitoss as a bone graft expander for noninstrumented posterolateral lumbar fusions (earlier study)
In a prior series from 2008, Epstein evaluated fusion rates for 60 patients undergoing average 5.4 level laminectomies with 1-2 level posterolateral noninstrumented fusions utilizing Vitoss/BMA/autograft. [2] Although radiographic pseudarthrosis was documented in nine (15%) patients on both dynamic X-rays and 2D-CT studies performed 3-12 months postoperatively, only one patient was sufficiently symptomatic to required secondary surgery (e.g., younger patient on early postoperative aspirin due to severe cardiac disease).
Efficacy of Local bone with Vitoss/B-TCP (bone graft extender) for posterior adolescent idiopathic scoliosis surgery
In a 2009 prospective randomized scoliosis pilot study (EBM-Level 1), Lerner et al. compared the clinical/radiographic results of utilizing Vitoss/ B-TCP (20 patients) with local bone versus autogenous iliac crest bone graft (ICBG) (20 patients) for adolescent idiopathic scoliosis (AIS) surgery. [6] With an average postoperative follow-up of 20 months, Vitoss/local bone graft resulted in equal fusion rates (e.g., only 1 pseudarthrosis) versus ICBG (e.g. no pseudarthrosis).
Efficacy of bone morphogenetic protein (BMP/INFUSE) and calcium phosphate salts for posterolateral lumbar fusion
In 2014, Kaiser et al. proposed using local laminectomy autograft, calcium-phosphate salts, and bone morphogenetic proteins (BMPs) to perform lumbar interbody fusions, thus avoiding the morbidity of harvesting autologous ICBG (AICB). [5] Although they noted comparable fusion rates using BMP, they cited increasing concern regarding BMPs risks of heterotopic bone formation. [8] Patients' comorbid factors included: obesity (19 patients), hypertension (HTN) (4 patients), Type II DM (2 patients), smoking (6 patients), steroid use (1 patient), and osteopenia (3 patients). CT-documented fusion (e.g. bridging bone) over the transverse processes was confirmed in 94% of patients either unilaterally or bilaterally; fusion rates for 1-3 segments were 88%, 93%, and 100%, respectively, with only 6% of segments showing no fusion. Furthermore, there were no complications attributed to NanOss. [7] Focusing on improved bone formation utilizing nanoceramics (NanOss) versus micron ceramics, they demonstrated similar osteoblast and osteoclast activity for NanOss and normal bone, noting that micron crystalline HA products were not as effective. They concluded that NanOss resulted in increased bone growth, reduced pseudarthrosis, and fewer infections.
Comparison of NanOss with Vitoss and other products as bone graft expanders
Comparable posterior cervical fusion rates utilizing Vitoss versus NanOss to supplement ICBG and BMA
In 2014, Epstein evaluated the efficacy of utilizing two bone graft expanders to achieve fusion in two separate sequential patient cohorts undergoing 1-3 level cervical laminectomy with posterior instrumented fusions (range 5-9 levels). [4] The first cohort of 72 patients received Vitoss/BMA/ICBG, while the next cohort of 20 patients received NanOss/BMA/ICBG. Utilizing dynamic X-ray and 2D-CT studies, the time to fusion for both groups were comparable (5.65 months vs. 5.35 months). 
CONCLUSION
Following multilevel lumbar laminectomies and 1-2 level posterolateral noninstrumented fusions, Vitoss (213 patients) and subsequently NanOss (45 patients) proved to be successful bone graft expanders, demonstrating nearly comparable fusion rates. Despite the smaller number of NanOss patients in this study, the comparable fusion efficacy and lack of significant postoperative complications make it a promising product to use in the future.
